NCT02413918 is a Phase 4 clinical trial of iloperidone in Bipolar Disorder, sponsored by The University of Texas Health Science Center at San Antonio.

Who is sponsoring NCT02413918?

NCT02413918 is sponsored by The University of Texas Health Science Center at San Antonio.

What drugs are being tested in NCT02413918?

Interventions in NCT02413918: iloperidone.

What condition does NCT02413918 study?

NCT02413918 studies Bipolar Disorder.

Is NCT02413918 still recruiting?

NCT02413918 is currently completed. Last updated 12 January 2018.

Are results published for NCT02413918?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-01-12 · How we verify

NCT02413918

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Open Label Study of Iloperidone (IL) as Adjunctive Treatment in Mixed States (MS) of Bipolar Disorder (BD)

Completed Phase 4 Results posted Last updated 12 January 2018

What this trial tests

Phase 4 trial testing iloperidone in Bipolar Disorder in 41 participants. Completed in 1 April 2015.

Timeline

1 April 2012

Primary endpoint
1 April 2015

1 April 2015

Quick facts

Lead sponsor	The University of Texas Health Science Center at San Antonio
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	41
Start date	1 April 2012
Primary completion	1 April 2015
Estimated completion	1 April 2015
Sites	1 location across United States

Drugs / interventions tested

iloperidone (ILOPERIDONE) — full drug profile →

Conditions studied

Bipolar Disorder — all drugs for Bipolar Disorder →

Sponsor

The University of Texas Health Science Center at San Antonio

Who can join

18 and older, any sex, with Bipolar Disorder. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Measure of Response by Change From Baseline to End of Study in BISS Depression and Mania Scale Scores
Time frame: Baseline and 20 weeks
The Bipolar Inventory of Symptoms Scale is a reliable and valid measure which assesses Depression and Mania symptoms of bipolar disorder. There are 42 items; each item is rated on a 0-4 scale. The BISS is a clinician-rated instrument. The Scale is rated as follows: 0 Not at all 1. Slight 2. Mild 3. Moderate 4. Severe Each of the 42 items is rated separately, with a score, based on the most recen

Sponsor's own description

1. To assess the acute and long-term bimodal efficacy of iloperidone (IL), as an adjunct to ongoing treatment with lithium (Li) or divalproex (DIV) or lamotrigine (LAM) or any combination of the three thereof, in a group of patients with an index episode of a mixed state in BD. 2. To assess background, baseline features, and behavioral components which characterize treatment response/non-response in the acute and long term management of MS

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Bipolar Disorder

Currently open trials in the same condition.

NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT06911931 — Visual Perception in Schizophrenia · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07479758 — Biomarker Research on Ultra-High-Field MRI Combined With Visual Perception Assessment in the Diagnosis and Treatment Out · recruiting
NCT07140913 — A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Featur · Phase 3 · recruiting

Other The University of Texas Health Science Center at San Antonio trials

Trials by the same sponsor.

NCT07280897 — SCIPI Implementation and Evaluation: A Multi-site Proof-of-Concept Pilot Trial · NA · not yet recruiting
NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07056699 — SGLT2i, Pioglitazone, and Ketone Production in T1D · Phase 3 · not yet recruiting
NCT06609343 — Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis · Phase 1, PHASE2 · not yet recruiting
NCT07437053 — Sarcopenia in Chronic Kidney Disease (CKD) Patients · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02413918 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas Health Science Center at San Antonio
Last refreshed: 12 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02413918.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing